Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

993 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668.
Reid JM, Walden CA, Qin R, Ziegler KL, Haslam JL, Rajewski RA, Warndahl R, Fitting CL, Boring D, Szabo E, Crowell J, Perloff M, Jong L, Bauer BA, Mandrekar SJ, Ames MM, Limburg PJ; Cancer Prevention Network. Reid JM, et al. Among authors: szabo e. Cancer Prev Res (Phila). 2011 Mar;4(3):347-53. doi: 10.1158/1940-6207.CAPR-10-0313. Cancer Prev Res (Phila). 2011. PMID: 21372034 Free PMC article. Clinical Trial.
A phase I study of myo-inositol for lung cancer chemoprevention.
Lam S, McWilliams A, LeRiche J, MacAulay C, Wattenberg L, Szabo E. Lam S, et al. Among authors: szabo e. Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1526-31. doi: 10.1158/1055-9965.EPI-06-0128. Cancer Epidemiol Biomarkers Prev. 2006. PMID: 16896044 Clinical Trial.
Comparative bioavailability of sulindac in capsule and tablet formulations.
Reid JM, Mandrekar SJ, Carlson EC, Harmsen WS, Green EM, McGovern RM, Szabo E, Ames MM, Boring D, Limburg PJ; Cancer Prevention Network. Reid JM, et al. Among authors: szabo e. Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):674-9. doi: 10.1158/1055-9965.EPI-07-2510. Cancer Epidemiol Biomarkers Prev. 2008. PMID: 18349286 Free PMC article.
Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic.
Meyskens FL Jr, Curt GA, Brenner DE, Gordon G, Herberman RB, Finn O, Kelloff GJ, Khleif SN, Sigman CC, Szabo E; C-Change Chemoprevention Clinical Trials and Biomarkers Subcommittee. Meyskens FL Jr, et al. Among authors: szabo e. Cancer Prev Res (Phila). 2011 Mar;4(3):311-23. doi: 10.1158/1940-6207.CAPR-09-0014. Cancer Prev Res (Phila). 2011. PMID: 21372031 Free PMC article.
Lung cancer chemoprevention with celecoxib in former smokers.
Mao JT, Roth MD, Fishbein MC, Aberle DR, Zhang ZF, Rao JY, Tashkin DP, Goodglick L, Holmes EC, Cameron RB, Dubinett SM, Elashoff R, Szabo E, Elashoff D. Mao JT, et al. Among authors: szabo e. Cancer Prev Res (Phila). 2011 Jul;4(7):984-93. doi: 10.1158/1940-6207.CAPR-11-0078. Cancer Prev Res (Phila). 2011. PMID: 21733822 Free PMC article. Clinical Trial.
Randomized phase II trial of sulindac for lung cancer chemoprevention.
Limburg PJ, Mandrekar SJ, Aubry MC, Ziegler KL, Zhang J, Yi JE, Henry M, Tazelaar HD, Lam S, McWilliams A, Midthun DE, Edell ES, Rickman OB, Mazzone P, Tockman M, Beamis JF, Lamb C, Simoff M, Loprinzi C, Szabo E, Jett J; Cancer Prevention Network. Limburg PJ, et al. Among authors: szabo e. Lung Cancer. 2013 Mar;79(3):254-61. doi: 10.1016/j.lungcan.2012.11.011. Epub 2012 Dec 20. Lung Cancer. 2013. PMID: 23261228 Free PMC article. Clinical Trial.
A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum.
Gillen DL, Meyskens FL, Morgan TR, Zell JA, Carroll R, Benya R, Chen WP, Mo A, Tucker C, Bhattacharya A, Huang Z, Arcilla M, Wong V, Chung J, Gonzalez R, Rodriguez LM, Szabo E, Rosenberg DW, Lipkin SM. Gillen DL, et al. Among authors: szabo e. Cancer Prev Res (Phila). 2015 Mar;8(3):222-30. doi: 10.1158/1940-6207.CAPR-14-0148. Epub 2015 Jan 20. Cancer Prev Res (Phila). 2015. PMID: 25604134 Free PMC article. Clinical Trial.
993 results